interesting pricing gouging case

When many people read about the possible price point for Scenesse for EPP in the analyst / company reports, there was a collective sticker shock.

I'm not referring to the price of the drug in Italy, but the expected price of the drug if it gets formal FDA or EMA approval.

I had felt that it's one thing to price the drug to ensure a profit, but I wondered if it was really necessary to price the drug as high as some of the price points we've seen.

Now KV Pharmaceuticals, a stock that I got in at around $1.75 earlier this year to witness a 12 bagger (went over $13 a month later), is going to be investigated for price gouging if U.S. Senator Brown has his way.

Biotechs and pharmas cannot just price a drug at whatever price point they choose. It's a different industry than most other free market industries.

We're not sure what price point Clinuvel will select upon approval, but I hope they keep this in mind. In this day and age, it's much easier to mobolize a grassroots effort to get the attention of legislators.